^
Association details:
| Biomarker: | EML4-ALK variant 3 |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib
Excerpt:
The clinical response to crizotinib and survival data in ALK-positive patients was retrospectively analyzed....EML4-ALK-positive NSCLC (n = 96), patients harboring variant 3 or variant 5 displayed significantly lower PFS and OS than those with other variants (PFS, 8.6 vs. 11.3 months, p = 0.046; OS, 31.0 vs. 37.6 months, p = 0.026).
DOI:
10.1007/s11523-019-00631-x
Source:
Title:
Molecular predictors of long-term response to crizotinib in ALK+ advanced non-small cell lung cancer (NSCLC) patients.
Excerpt:
Twenty-four pts with stage III-IV ALK+ NSCLC received crizotinib either as first or second-line treatment. Median duration of therapy was 11.1 mos (range 1-40.3 mos) and median PFS was 13.6 mos at data cut-off. The median PFS in LR, R and NR was 32.6 vs. 11.7 vs. 1.6 mos, respectively. EML4-ALK variant 3, involved in ALK resistance, was identified at baseline and relapse in 3 NR pts.
DOI:
10.1200/JCO.2018.36.15_suppl.e21038
Trial ID:
